Micafungin Pharmazac 50 Mg (Micafungin)

Micafungin blocks the fungal enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. This disruption weakens the wall, causing osmotic instability and cell death, while human cells are unaffected because they lack this enzyme.

The specific dose and duration of Micafungin Pharmazac 50 mg are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. No standard dosing regimen is provided here.

Safety data for micafungin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use is only recommended when the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to membrane sterols. Echinocandins like micafungin are generally well‑tolerated, have minimal drug‑drug interactions, and are effective against many Candida species, including some azole‑resistant strains.

The product should be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the solution must be administered, allow it to reach room temperature before use, following aseptic technique.

Micafungin Pharmazac 50 mg is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central line, typically over a period of 30 to 60 minutes, according to the prescriber's instructions and institutional protocols.

Serious adverse events include hepatotoxicity (significant liver enzyme elevation or liver failure), severe hypersensitivity reactions such as anaphylaxis, and infusion‑related reactions like hypotension or bronchospasm. Patients should be monitored for signs of liver dysfunction, rash, respiratory distress, or sudden blood pressure changes during and after infusion.

Micafungin is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in patients receiving other echinocandins or strong CYP3A4 inducers without appropriate monitoring.